Efficacy of Pfizer-BioNTech in SARS-CoV-2 Delta cluster

Efficacy of Pfizer-BioNTech in SARS-CoV-2 Delta cluster

ABSTRACT: Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) sublineage B.1.617.2 or Delta, a variant that began circulating in India and is becoming dominant in the USA, has been responsible for significant morbidity and mortality. In May 2021, the Delta variant was upgraded to a variant...

Full description

Saved in:
Bibliographic Details
Main Authors: Hannah E. Landsberg, MSN, MPH, Jacquelyn Turcinovic, B.S., Madison Sullivan, MPH, John H. Connor, Ph.D., Davidson H. Hamer, MD, Judy T. Platt, MD
Format: article
Language:EN
Published: Elsevier 2022
Subjects:
COVID-19
Sequencing
Delta variant
Variant of concern
PCR testing
Contact tracing
Infectious and parasitic diseases
RC109-216
Online Access:https://doaj.org/article/52bd5f1be98c4a7b8d31ec631ce2ec32
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doaj.org/article/52bd5f1be98c4a7b8d31ec631ce2ec32

Similar Items